Cel Sci Corporation (CVM)

[Biobonic]

To quote Aaron Rodgers R-E-L-A-X

Couple of points:

In the Ergomed recent filing, along with Cel-Sci in the Co-Development Program three other companies were also listed.

Two of those three also have percentage of completion in their detail.

Ergomed is exiting the Co-Development Program and wanted to show the percentage of completion of each participant.
They are showing that this program is nearly complete and the financial risk these trials could cost Ergomed are mitigated and coming to an end.

One trial, Modus is listed as 98% complete. Modus announced in May 2019 that the study failed... Ergomed has responsibility for record keeping and finishing up all that entails.

I don't believe Ergomed erred in calculating the original posting of 96% completion for the Cel-Sci study.

Second Point: Ergomed is building their CRO business on their differentiation. In reading their reports, Ergomed is working at providing caring and compassionate clinical trial experience. The result of this is a lower dropout rate. This saves the trial sponsor time and money. A low dropout rate in a trial of this magnitude and length will be a great selling point for Ergomed in future bids for trials. I do not believe this trial is experiencing an unusually high dropout rate.

Third point: People die from other causes than cancer.

How will non-cancer deaths be factored in the final results?

Cardiovascular diseases
31.8%
Cancers
17.08%
Respiratory diseases
7%
Lower respiratory infections
4.57%
Dementia
4.49%
Digestive diseases
4.25%
Neonatal deaths
3.19%
Diarrheal diseases
2.81%
Diabetes mellitus
2.45%
Liver disease
2.36%
Road incidents
2.22%